Table 2. HLA-identical sibling... | American Society of Hematology

Table 2.

HLA-identical sibling recipients

	N, 3y	Survival, %	LFS, %	Relapse, %	TRM, %
Total	100	71	59	21	20
Stage
CP1	93	75	63	17	20
No CP1	7	46	35	49	16
Sex mismatch
Male/female	25	71	62	14	24
Other combinations	75	71	58	24	18
CMV status, R/D
+/+	31	71	58	24	18
-/+	6	68	52	41	7
+/-	16	80	72	13	16
-/-	30	68	59	15	26
IFN
No	69	70	57	22	21
Yes	19	76	71	11	19
TBI
No	41	77	63	23	14
Yes	59	66	56	20	25
Acute GVHD
TCD+/- CSA/MTX	14	64	40	40	20
CSA alone	27	60	57	13	30
CSA+ MTX	57	78	65	21	14
TCD
No	86	72	62	18	20
Yes	14	64	40	40	20
Interval diagnosis to SCT, mo
0-6	44	73	66	17	16
6-12	25	68	56	26	18
Longer than 12	31	71	52	23	25

	N, 3y	Survival, %	LFS, %	Relapse, %	TRM, %
Total	100	71	59	21	20
Stage
CP1	93	75	63	17	20
No CP1	7	46	35	49	16
Sex mismatch
Male/female	25	71	62	14	24
Other combinations	75	71	58	24	18
CMV status, R/D
+/+	31	71	58	24	18
-/+	6	68	52	41	7
+/-	16	80	72	13	16
-/-	30	68	59	15	26
IFN
No	69	70	57	22	21
Yes	19	76	71	11	19
TBI
No	41	77	63	23	14
Yes	59	66	56	20	25
Acute GVHD
TCD+/- CSA/MTX	14	64	40	40	20
CSA alone	27	60	57	13	30
CSA+ MTX	57	78	65	21	14
TCD
No	86	72	62	18	20
Yes	14	64	40	40	20
Interval diagnosis to SCT, mo
0-6	44	73	66	17	16
6-12	25	68	56	26	18
Longer than 12	31	71	52	23	25

Data reflect survival and LFS Kaplan-Meier estimated probabilities and relapse and TRM cumulative incidence estimates at 3 years.

N, 3 y indicates number of patients at risk at 3 years; R/D, recipient/donor.